Cite
HARVARD Citation
Masson, R. et al. (2022). Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet neurology. 21 (12), pp. 1110-1119. [Online].